Collaborative Arrangements and Acquisitions - Parion Sciences, Inc. (Details) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 04, 2015	Jun. 30, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative revenues			$ 27,286,000	$ 675,000	$ 259,831,000	$ 749,000
Provision for income taxes			4,337,000	18,130,000	8,322,000	23,615,000
Business Combination, Consideration Transferred [Abstract]
Intangible assets			284,340,000		284,340,000		$ 284,340,000
Parion Sciences, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, up-front payment	$ 80,000,000	$ 80,000,000
Prior to marketing approval, time period of notice required to terminate (in days)		90 days
Subsequent to marketing approval, time period of notice required to terminate (in days)		180 days
Change of control prior to clinical trial, time period of notice required to terminate (in days)		30 days
Term of agreement following first commercial sale (in years)		10 years
Collaborative revenues					20,000,000
Provision for income taxes					7,400,000
Business Combination, Consideration Transferred [Abstract]
Intangible assets	255,300,000
Noncontrolling interest, fair value	164,300,000
Deferred tax liabilities, net	91,000,000
Other liabilities / assets, net	$ 10,500,000
ENaC Inhibitors in CF | Parion Sciences, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, development and regulatory potential milestone payments maximum		$ 490,000,000
Collaborative arrangement regulatory potential milestone payments maximum, global filling and approval		360,000,000
Enac Inhibitors in Non Cf | Parion Sciences, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, development and regulatory potential milestone payments maximum		370,000,000
Additional Enac Inhibitors | Parion Sciences, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, development and regulatory potential milestone payments maximum		$ 230,000,000
Variable Interest Entity, Primary Beneficiary
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Provision for income taxes			8,132,000	$ 17,511,000	8,523,000	$ 20,573,000
Business Combination, Consideration Transferred [Abstract]
Intangible assets			284,340,000		$ 284,340,000		$ 284,340,000
Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative revenues			20,000,000
Provision for income taxes			$ 7,400,000
Business Combination, Consideration Transferred [Abstract]
Intangible assets								$ 255,300,000